Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Vastag

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
Journal of the National Cancer Institute|January 5, 2006
Qualified health claim rulings leave little leeway for label languageBrian Vastag
Nature Biotechnology|February 9, 2006
Industry warily eyes new Medicare drug planBrian Vastag
JAMA|February 28, 2002
Study concludes that moderate PSA levels are unrelated to prostate cancer outcomesBrian Vastag
Nature Biotechnology|November 10, 2006
HSP-90 inhibitors promise to complement cancer therapiesBrian Vastag
Nature Biotechnology|September 12, 2006
New clinical trials policy at FDABrian Vastag
Hospitals & Health Networks|January 24, 2007
Tour of dutyBrian Vastag
Journal of the National Cancer Institute|May 18, 2006
Attention turns to lung cancer in nonsmokersBrian Vastag
Nature Biotechnology|May 9, 2006
Tuft's report backs FDA fast-track, but post-marketing concerns loomBrian Vastag
JAMA|April 10, 2002
Decade of work shows depression is physicalBrian Vastag
Nature Biotechnology|June 10, 2006
Monoclonals expand into neural disordersBrian Vastag
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
Journal of the National Cancer Institute|January 5, 2006
Qualified health claim rulings leave little leeway for label languageBrian Vastag
Nature Biotechnology|February 9, 2006
Industry warily eyes new Medicare drug planBrian Vastag
JAMA|February 28, 2002
Study concludes that moderate PSA levels are unrelated to prostate cancer outcomesBrian Vastag
Nature Biotechnology|November 10, 2006
HSP-90 inhibitors promise to complement cancer therapiesBrian Vastag
Nature Biotechnology|September 12, 2006
New clinical trials policy at FDABrian Vastag
Hospitals & Health Networks|January 24, 2007
Tour of dutyBrian Vastag
Journal of the National Cancer Institute|May 18, 2006
Attention turns to lung cancer in nonsmokersBrian Vastag
Nature Biotechnology|May 9, 2006
Tuft's report backs FDA fast-track, but post-marketing concerns loomBrian Vastag
JAMA|April 10, 2002
Decade of work shows depression is physicalBrian Vastag
Nature Biotechnology|June 10, 2006
Monoclonals expand into neural disordersBrian Vastag
Pageof 14